What's Happening?
AN2 Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the 2026 Stifel Virtual Targeted Oncology Forum. Eric Easom, the company's Co-Founder, Chairman, President,
and CEO, will engage in a fireside chat during the event on May 19, 2026. The company focuses on developing novel small-molecule therapeutics using its boron chemistry platform, targeting hematologic diseases, infectious diseases, and oncology. AN2 Therapeutics is advancing three Phase 2 studies and has two preclinical candidates, with ongoing research in oncology, bone disorders, and infectious diseases.
Why It's Important?
AN2 Therapeutics' participation in the forum highlights its commitment to addressing critical unmet medical needs through innovative drug development. The company's focus on small-molecule therapeutics derived from boron chemistry represents a unique approach in the biopharmaceutical industry. By participating in the forum, AN2 Therapeutics aims to engage with investors and stakeholders, potentially attracting interest and investment in its research and development efforts. The company's progress in clinical trials and preclinical research could lead to significant advancements in treating various diseases, benefiting patients and the healthcare industry.
